| Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patients J Panse, K Friedrichs, A Marx, Y Hildebrandt, T Luetkens, K Bartels, ... British journal of cancer 99 (6), 930-938, 2008 | 155 | 2008 |
| Cancer‐testis antigen expression and its epigenetic modulation in acute myeloid leukemia D Atanackovic, T Luetkens, B Kloth, G Fuchs, Y Cao, Y Hildebrandt, ... American journal of hematology 86 (11), 918-922, 2011 | 150 | 2011 |
| Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells D Atanackovic, Y Hildebrandt, A Jadczak, Y Cao, T Luetkens, S Meyer, ... Haematologica 95 (5), 785, 2010 | 138 | 2010 |
| Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma D Atanackovic, T Luetkens, N Kröger Leukemia 28 (5), 993-1000, 2014 | 130 | 2014 |
| Longitudinal analysis and prognostic effect of cancer-testis antigen expression in multiple myeloma D Atanackovic, T Luetkens, Y Hildebrandt, J Arfsten, K Bartels, C Horn, ... Clinical Cancer Research 15 (4), 1343-1352, 2009 | 112 | 2009 |
| The cytokine/chemokine pattern in the bone marrow environment of multiple myeloma patients Y Cao, T Luetkens, S Kobold, Y Hildebrandt, M Gordic, N Lajmi, S Meyer, ... Experimental hematology 38 (10), 860-867, 2010 | 110 | 2010 |
| NY‐CO‐58/KIF2C is overexpressed in a variety of solid tumors and induces frequent T cell responses in patients with colorectal cancer S Gnjatic, Y Cao, U Reichelt, EF Yekebas, C Nölker, AH Marx, ... International journal of cancer 127 (2), 381-393, 2010 | 99 | 2010 |
| CD4+ CD25+ FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation D Atanackovic, Y Cao, T Luetkens, J Panse, C Faltz, J Arfsten, K Bartels, ... haematologica 93 (3), 423-430, 2008 | 97 | 2008 |
| Immunomodulatory molecule PD-L1 is expressed on malignant plasma cells and myeloma-propagating pre-plasma cells in the bone marrow of multiple myeloma patients S Yousef, J Marvin, M Steinbach, A Langemo, T Kovacsovics, M Binder, ... Blood cancer journal 5 (3), e285-e285, 2015 | 95 | 2015 |
| Decrease of CD4+ FOXP3+ T regulatory cells in the peripheral blood of human subjects undergoing a mental stressor E Freier, CS Weber, U Nowottne, C Horn, K Bartels, S Meyer, ... Psychoneuroendocrinology 35 (5), 663-673, 2010 | 92 | 2010 |
| Chimeric Antigen Receptor (CAR) therapy for multiple myeloma D Atanackovic, SV Radhakrishnan, N Bhardwaj, T Luetkens British journal of haematology 172 (5), 685-698, 2016 | 91 | 2016 |
| CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide SV Radhakrishnan, T Luetkens, SD Scherer, P Davis, ER Vander Mause, ... Nature communications 11 (1), 798, 2020 | 83 | 2020 |
| Autoantibodies against tumor-related antigens: incidence and biologic significance S Kobold, T Lütkens, Y Cao, C Bokemeyer, D Atanackovic Human immunology 71 (7), 643-651, 2010 | 73 | 2010 |
| Low-affinity CAR T cells exhibit reduced trogocytosis, preventing rapid antigen loss, and increasing CAR T cell expansion ML Olson, ERV Mause, SV Radhakrishnan, JD Brody, AP Rapoport, ... Leukemia 36 (7), 1943-1946, 2022 | 72 | 2022 |
| Cancer‐testis antigen MAGEC 2 promotes proliferation and resistance to apoptosis in Multiple Myeloma N Lajmi, T Luetkens, S Yousef, J Templin, Y Cao, Y Hildebrandt, K Bartels, ... British journal of haematology 171 (5), 752-762, 2015 | 70 | 2015 |
| An optimized assay for the enumeration of antigen-specific memory B cells in different compartments of the human body Y Cao, M Gordic, S Kobold, N Lajmi, S Meyer, K Bartels, Y Hildebrandt, ... Journal of immunological methods 358 (1-2), 56-65, 2010 | 70 | 2010 |
| Simultaneous cytoplasmic and nuclear protein expression of melanoma antigen‐A family and NY‐ESO‐1 cancer‐testis antigens represents an independent marker for poor survival in … S Laban, D Atanackovic, T Luetkens, R Knecht, CJ Busch, M Freytag, ... International journal of cancer 135 (5), 1142-1152, 2014 | 67 | 2014 |
| Role of immunotherapy in Ewing sarcoma E Morales, M Olson, F Iglesias, S Dahiya, T Luetkens, D Atanackovic Journal for ImmunoTherapy of Cancer 8 (2), 2020 | 66 | 2020 |
| Expression, epigenetic regulation, and humoral immunogenicity of cancer-testis antigens in chronic myeloid leukemia T Luetkens, P Schafhausen, F Uhlich, T Stasche, R Akbulak, BM Bartels, ... Leukemia research 34 (12), 1647-1655, 2010 | 62 | 2010 |
| 5‐azacytidine promotes an inhibitory T‐cell phenotype and impairs immune mediated antileukemic activity T Stübig, A Badbaran, T Luetkens, Y Hildebrandt, D Atanackovic, ... Mediators of inflammation 2014 (1), 418292, 2014 | 53 | 2014 |
